Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4,130 JPY | +1.00% | +0.19% | +1.87% |
Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
Apr. 26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Sales 2024 * | 4,099B 26.14B | Sales 2025 * | 4,028B 25.69B | Capitalization | 6,415B 40.9B |
---|---|---|---|---|---|
Net income 2024 * | 134B 855M | Net income 2025 * | 234B 1.49B | EV / Sales 2024 * | 2.48 x |
Net Debt 2024 * | 3,771B 24.04B | Net Debt 2025 * | 3,438B 21.92B | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
46.4
x | P/E ratio 2025 * |
27.6
x | Employees | 49,095 |
Yield 2024 * |
4.6% | Yield 2025 * |
4.64% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | +1.10% | ||
1 week | +0.29% | ||
Current month | -1.20% | ||
1 month | -0.60% | ||
3 months | -4.17% | ||
6 months | +3.66% | ||
Current year | +1.97% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 15 M€ | +10.29% | ||
5.00% | 284 M€ | +25.75% | ||
3.80% | 1,552 M€ | +20.02% | ||
3.43% | 251 M€ | +13.17% | ||
3.26% | 57 M€ | +22.54% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 4,130 | +1.00% | 2 034 900 |
24-04-26 | 4,089 | -0.02% | 3,185,300 |
24-04-25 | 4,090 | -1.09% | 2,910,500 |
24-04-24 | 4,135 | +0.32% | 3,228,000 |
24-04-23 | 4,122 | -0.15% | 2,747,100 |
Delayed Quote Japan Exchange, April 29, 2024 at 10:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.97% | 40.76B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 4502 Stock